期刊文献+

唑来膦酸对成纤维细胞作用的影响

The influence of zoledronic acid on proliferation, migration and apoptosis of fibroblasts
下载PDF
导出
摘要 目的:分析唑来膦酸对成纤维细胞的影响,探讨唑来膦酸对软组织损伤及引起创口软组织愈合困难的可能机制.方法:体外常规培养NIH 3T3成纤维细胞.流式细胞凋亡实验检测加入唑来膦酸后成纤维细胞凋亡的变化.MTT法检测加入唑来膦酸条件下成纤维细胞增殖活性的变化,细胞划痕实验观察唑来膦酸对成纤维细胞迁移能力的影响.采用SPSS 17.0软件包对数据进行统计学分析.结果:在药物浓度为5~50 μmol/L范围时,随着药物浓度升高,唑来膦酸促进成纤维细胞凋亡,抑制增殖、迁移的作用逐渐增强.结论:唑来膦酸能对软组织造成损伤,可引起拔牙创软组织愈合困难. PURPOSE: Bisphosphonates are commonly used to treat bone-derived malignant tumors currently. In recent years, with the widespread use of these drugs, reports on the difficulty of wound healing (DWH) increase remarkably. However, the mechanism is still unclear. The soft tissue injury was suspected to cause DWH in many recent reports. This experiment was designed to explore the influence of zoledronic acid on fibroblast, and investigate the possible mechanisms leading to DWH. METHODS: NIH 3T3 fibroblasts were routinely cultured in vitro. The influence of zoledronic acid on apoptosis, proliferation and migration of fibroblast were tested with flow cytometry, MTT and cell migration assay, respectively. The results of each experimental group were compared with the control group using SPSS 17.0 software package. RESULTS: At a concentration of 5~50 μmol/L, zoledronic acid could dose -dependently inhibit the activity of fibroblast proliferation and migration, and up-regulate apoptosis with significant difference (P<0.05). CONCLUSIONS: Zoledronic acid can up-regulate cell apoptosis, inhibit proliferation and migration of fibroblast, suggesting that soft tissue impairment might contribute to the occurrence of DWH.
作者 郎淼杰 区跃坚 LANG Miao -jie;OU Yue-jian(Department of Stomatology, Huzhou Central Hospital, Huzhou 313000, Zhejiang Province, China)
出处 《上海口腔医学》 CAS CSCD 北大核心 2019年第5期490-493,共4页 Shanghai Journal of Stomatology
关键词 唑来膦酸 成纤维细胞 凋亡 增殖 迁移 Zoledronic acid Fibroblast Apoptosis Proliferation Migration
  • 相关文献

参考文献3

二级参考文献44

  • 1阮敏,季彤,张陈平.双膦酸盐性颌骨坏死的研究进展[J].上海口腔医学,2006,15(6):663-667. 被引量:6
  • 2Marx RE. Pamidronate ( Aredia ) and zoledronate ( Zometa ) induced avascular necrosis of the jaws:a growing epidemic. J Oral Maxillofac Surg,2003,61 : 1115-1118.
  • 3方强.危重病护理学.杭州:浙江大学出版社,2001.
  • 4Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med ,2005,34 : 120-123.
  • 5Pires FR, Miranda AMMA, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Diseases ,2005,11:365-369.
  • 6Ruggiero SL, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Practice,2006,2:7-14.
  • 7Yamada K, Kohno N. Efficacy of bisphosphonates for bone pain control. Nippon Rinsho, 2007,65(1) : 152-156.
  • 8Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Crit Rev Oncol Hematol, 2007,62(2) : 148-152.
  • 9Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med, 2005,353(1) :99- 102.
  • 10Sala A, Mattano LA Jr, Barr RD. Osteonecrosis in children and adolescents with cancer an adverse effect of systemic therapy. Eur J Cancer, 2007,43(4) :683- 689.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部